Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levorphanol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 9/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 9/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 8/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 8/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 8/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 8/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 8/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 5/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SCN1A | P35498 | 2/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 2/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levorphanol SCHEMBL5171217 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL24335 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL14326930 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL16310821 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL21095576 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL12232844 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL22791693 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL22722062 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Dextrorphan SCHEMBL20535964 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemorphan SCHEMBL46201 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190242892-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2019-08-08 | — | — | US | claimed |
| EP-2747754-B1 | MORPHINAN-DERIVATIVES FOR TREATING DIABETES AND RELATED DISORDERS | DEUTSCHE DIABETES-FORSCHUNGSGESELLSCHAFT E V (DE) | 2017-04-05 | — | — | EP | claimed |
| US-9370511-B2 | Morphinan-derivatives for treating diabetes and related disorders | DEUTSCHE DIABETES-FORSCHUNGSGESELLSCHAFT E.V. (DE) | 2016-06-21 | — | — | US | claimed |
| US-20150087669-A1 | Morphinan-derivatives for treating diabetes and related disorders | DEUTSCHE DIABETES-FORSCHUNGSGESELLSCHAFT E.V. (DE) | 2015-03-26 | — | — | US | claimed |
| US-20140030262-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2014-01-30 | — | — | US | claimed |
| US-20100092478-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-15 | — | — | US | claimed |
| US-20240060975-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-02-22 | — | — | US | disclosed |
| US-20220196652-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-06-23 | — | — | US | disclosed |
| EP-3383851-B1 | DEXTRORPHAN-DERIVATIVES WITH SUPPRESSED CENTRAL NERVOUS ACTIVITY | HEINRICH HEINE UNIV DUESSELDORF (DE) | 2021-07-14 | — | — | EP | disclosed |
| US-20210085691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2021-03-25 | — | — | US | disclosed |
| US-20200393462-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200297734-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2020-09-24 | — | — | US | disclosed |
| EP-2880033-B1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20150087669-A1 | Morphinan-derivatives for treating diabetes and related disorders | DEUTSCHE DIABETES-FORSCHUNGSGESELLSCHAFT E.V. (DE) | 2015-03-26 | — | — | US | disclosed |
| EP-2747754-A1 | MORPHINAN-DERIVATIVES FOR TREATING DIABETES AND RELATED DISORDERS | Heinrich-Heine-Universität Düsseldorf (DE) | 2014-07-02 | — | — | EP | disclosed |
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20140030262-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2013029762-A1 | MORPHINAN-DERIVATIVES FOR TREATING DIABETES AND RELATED DISORDERS | HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF (DE) | 2013-03-07 | — | — | WO | disclosed |
| EP-2561866-A1 | Morphinan-derivatives for treating diabetes and related disorders | Heinrich-Heine-Universität Düsseldorf (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-20100092478-A1 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297734-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | GRIN3A, OPRK1, GRIN2B | OPRM1 14/4885GRIN1 13/4885GRIN2A 19/4885 |
| US-20210085691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | GRIN2B, GRIN3A, GRIN1 | OPRM1 25/4885GRIN1 3/4885GRIN2A 12/4885 |
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | QPCT, UBXN1, NQO2 | OPRM1 5/4885GRIN1 1056/4885GRIN2A 1258/4885 |
| US-20150087669-A1 | Morphinan-derivatives for treating diabetes and related disorders | INSR, GPR119, OPRM1 | OPRM1 3/4885GRIN1 5/4885GRIN2A 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.